RankAlpha logo
Back to Rankings

NERV

Minerva NeurosciencesA
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
View Chart
Current thesis
Successful Phase​‑3 outcomes or clear positive interim data plus access to committed financing would support upside toward the analyst high (12.46) as market confidence and re​‑rating follow clinical validation.
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta -5.8.
What can break
Adverse Phase​‑3 efficacy or safety results
Momentum
86
Value
42
Sentiment
66
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $4.59 · Bull $12.46 · Bear $2.50
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-03-11 • Model: RankAlpha Sentiment AI
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $4.50
Why
Momentum86 · Δ7d -5.8
Value42 · Δ7d +0.1
Sentiment66 · Δ7d +5.4
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
86
34% active weight
Current posture
7d trendSoftening
Δ7d
-5.8
Δ21d
+25.3
Value
42
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
66
33% active weight
Current posture
7d trendImproving
Δ7d
+5.4
Δ21d
+8.0
Why this grade

Composite grade A. Momentum 85.6 / Value 41.9 / Sentiment 65.7

Fundamentals (TTM)
As of 2026-06-01
Market Cap
$225.49M
Beta
-0.24
Shares Out
6.99M
P/E (TTM)
2.7
P/S (TTM)
-
P/FCF (TTM) · Derived
-17.19
Rev YoY
-
EPS YoY
-112.2%
Gross Margin
-
Op Margin
-
Net Debt
$38.64M
Current Ratio
4.87
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology